Retatrutide and Fatty Liver (MASLD): What the Liver Fat Data Shows

Fatty liver is common, quiet and stubborn. Many people learn they have it by accident, from a scan or blood test, and then hear one piece of advice: lose weight. That advice is right, and it is hard to follow. The retatrutide fatty liver data drew attention because it shows what happens when weight loss is large: in one Phase 2 study, liver fat fell 82% on average in 24 weeks on the top dose, and 86% of those people reached a normal level.

Those results are real, and so are their limits. The study scanned 98 livers with MRI and took no biopsies, so it shows fat leaving the liver, not scarring healing. Here is what that means for yours.

MASLD vs MASH: what the new names mean

Fatty liver disease got new names in 2023. A global panel led by the major US, European and Latin American liver societies renamed NAFLD as MASLD, metabolic dysfunction-associated steatotic liver disease, partly because many panelists found "nonalcoholic" and "fatty" stigmatizing. MASLD means fat has built up in the liver alongside at least 1 of 5 cardiometabolic risk factors, such as excess weight, type 2 diabetes or high blood pressure.

MASH, metabolic dysfunction-associated steatohepatitis, replaced NASH. It is MASLD plus inflammation and liver cell injury, the stage that can drive scarring (fibrosis) and, over years, cirrhosis.

That split is the key to reading the retatrutide data. The study measured the fat precisely, not the inflammation or scarring that decide long-term liver health.

What the retatrutide fatty liver study measured

It came from inside a larger weight-loss trial. The 48-week Phase 2 obesity trial enrolled 338 adults with obesity or overweight and no type 2 diabetes. Of those, 98 had at least 10% liver fat on MRI-PDFF, a scan that measures what share of the liver is fat, and joined a liver substudy published in Nature Medicine in 2024.

They were randomly assigned to placebo or to 1, 4, 8 or 12 mg of retatrutide once a week, with doses stepped up every 4 weeks. At the start they averaged 46.6 years old, a BMI of 38.4 and 19.1% liver fat, almost 4 times the 5% line for normal. Everyone also got diet and activity counseling.

Average relative change in liver fat on MRI; normal means under 5%. Source: Sanyal et al., Nature Medicine 2024.

Every dose beat placebo at 24 weeks, the main endpoint. Look at the 8 mg and 12 mg rows: both groups had lost about 18% of their weight by then, and both cut liver fat by about 82%. That pattern, liver fat following weight, runs through the whole study.

Does retatrutide get rid of fatty liver?

On MRI, for most people on higher doses, yes. By week 24, liver fat was under 5% in 79% of people on 8 mg and 86% on 12 mg, against none on placebo. By week 48 those shares were 89% and 93%. Arun Sanyal, the VCU hepatologist who led the substudy, put the goal this way: "we could wipe out the fat very early in the course of this disease before it becomes a real threat to the liver."

Smaller drops counted too. At 24 weeks, 71% to 100% on retatrutide had cut liver fat by at least 30%, against 4% on placebo. That line matters: in a 2021 analysis of 7 early-phase MASH trials, people who crossed it were far more likely to improve on biopsy (51% versus 14%).

Three details matter if you are tracking your liver:

• It clears early. Most of the drop came in the first 24 weeks and held through week 48 in people still on treatment, though only 43.9% had a usable 48-week scan.
• It clears before your weight does. People who reached normal liver fat by week 24 still had an average BMI of 31.0 to 32.9.
• Stopping is a blind spot. Liver fat was not measured after treatment ended, and some weight returned within 4 weeks of the last dose.

Why liver fat follows weight loss, and where glucagon fits

Weight loss explains most of the liver fat drop. The fall in liver fat tracked weight loss closely (a correlation of 0.80 at 24 weeks, where 1.0 is a perfect match) and deep belly fat loss almost as closely (0.79). It leveled off at around 20% weight loss, as the liver neared the floor of how much fat it can shed. Metabolic markers moved with it: on 12 mg, fasting insulin fell 70.9% and triglycerides 49.4% by week 48.

This study cannot split the two effects. The authors say retatrutide's edge may come from bigger weight loss, from glucagon acting on the liver, or both.

What the MRI cannot tell you about MASH

Liver fat is not the same as liver damage. MRI-PDFF sees fat, not inflammation or scarring, and the study took no liver biopsies, which is how MASH trials confirm the disease and grade fibrosis. Most participants also had early disease: only 7 of 98 had a FIB-4 score above 1.3 or an ELF score above 9.8, cutoffs used to rule out advanced scarring.

The study was also small, US-only and 98% white, made no statistical correction for running many tests, and the authors call the results "hypothesis-generating and not definitive." Lilly designed, funded and ran it, and several authors are Lilly employees. If you have type 2 diabetes, retatrutide and type 2 diabetes covers the trials that included you.

Retatrutide vs tirzepatide and semaglutide for the liver

On liver fat alone, retatrutide's numbers are bigger. The Nature Medicine authors cite reported drops of about 47% after 52 weeks for tirzepatide and about 50% after 72 weeks for semaglutide, against 86% at 48 weeks on retatrutide 12 mg. They warn that different populations and designs limit the comparison.

The evidence gap runs the other way. Tirzepatide and semaglutide have biopsy results in people with MASH and scarring. Retatrutide does not.

Biopsy evidence is what earned today's MASH treatments their approvals. The FDA approved resmetirom (Rezdiffra) for noncirrhotic MASH with moderate to advanced fibrosis in March 2024 and granted semaglutide (Wegovy) accelerated approval for the same group in August 2025. Retatrutide needs its own outcome data first.

Is retatrutide safe for your liver?

In the Phase 2 trial, no liver warning sign appeared. In the liver substudy, average ALT and AST started in the normal range and did not change consistently compared with placebo. The authors found no sign of drug-induced liver injury in the full Phase 2 trial through 48 weeks.

The common side effects were digestive. Nausea hit 54.5% of people on 8 mg and 38.9% on 12 mg, against 5.3% on placebo, mostly mild to moderate; our guide to managing nausea covers what helps. One person on retatrutide developed acute gallbladder inflammation and had the gallbladder removed, a known class risk: tirzepatide's label links acute gallbladder disease with weight loss on tirzepatide and GLP-1 drugs.

The liver injury headlines are a different story. On June 19, 2026, the Chief Health Officer of Victoria, Australia, reported six cases of acute liver injury since January 2026 in people using unapproved products labelled Retatrutide, Reta, R-10 or R-20, bought online, through friends or on social media. The department suspects a contaminant, and product testing was underway at the time.

Those cases do not show what pure retatrutide does, and the trials do not show what is in a vial bought online. If you are weighing retatrutide for sale listings, that gap is the point: none of them is the product used in these trials, and Lilly says retatrutide "cannot be legally sold or marketed for human use." Victoria's health department advises against using them and tells anyone who continues to watch for symptoms and ask about liver function tests. For the full safety picture, see whether retatrutide is safe.

What comes next, and what you can do now

The real test for MASH has already started. SYNERGY-Outcomes, a Phase 3 trial that began in October 2025, is enrolling about 4,500 adults with higher-risk MASLD, picked by scans and blood tests rather than biopsy: at least 8% liver fat, an ELF score of 9 to 10.8 and raised liver stiffness. Within one master protocol, retatrutide and tirzepatide are each tested against placebo for about 224 weeks.

Its main question is whether treatment delays serious outcomes such as cirrhosis, fluid buildup in the belly, bleeding varices, a liver transplant or death. It also tracks liver fat, liver stiffness and ELF at week 104. The registry lists primary completion in August 2030, so answers are years away.

Lilly's 2026 announcements have not added liver results; they focused on weight, blood sugar, knee pain and sleep apnea. Lilly plans to file retatrutide with the FDA in the first quarter of 2027, and no approved version exists yet.

What you can do now depends on where your liver stands:

• Fatty liver without known scarring: weight loss is still the lever, and your liver may respond before you reach a goal weight. Ask your clinician about a FIB-4 or ELF test, which the study authors call well-validated for estimating scarring risk.
• MASH with moderate or advanced scarring: approved treatments already exist, so ask about them now rather than waiting for 2030.
• Wanting retatrutide through a legal route: ask about SYNERGY-Outcomes, which is recruiting, or have your doctor ask Lilly about single-patient expanded access for adults with a BMI of 35 or more and at least 2 serious obesity-related complications who have not responded to approved treatments and cannot join a trial.